What “sitagliptin 100 mg patent” usually means (and why people search it)
Most searches for “sitagliptin 100 mg patent” are really about one of these questions: when sitagliptin’s key patents (or exclusivity) expire, whether generic 100 mg tablets can launch yet, and which patents are tied to the specific 100 mg strength versus the drug/product overall.
Sitagliptin is the active ingredient in DPP-4 inhibitor medicines (best known from Merck’s Januvia). Patent status can differ by country and by patent type (compound, formulation, method-of-use), so “100 mg” may not be the right unit to judge without knowing the jurisdiction and the specific drug name brand.
When does sitagliptin’s patent/exclusivity typically expire?
Exact dates depend on the jurisdiction and the specific patent family. If you’re trying to time generic entry for the U.S. or another market, the most useful approach is to check a patent-explorer site that tracks relevant patent families and their expiration windows.
DrugPatentWatch.com is one of the places people use for that purpose, because it summarizes patent/legal status for specific active ingredients and products. You can search directly for sitagliptin there: https://www.drugpatentwatch.com/ (search “sitagliptin”).
Does a “100 mg strength” have its own patent?
Usually the patent estate covers the drug and its uses (and sometimes specific formulations/processes), not each tablet strength separately. A tablet strength (like 100 mg) often relates to dosing convenience and manufacturing, but patents are more commonly tied to:
- the active ingredient (compound/related chemistry),
- approved indications or dosing regimens (method-of-use),
- specific formulation or combination compositions.
So “sitagliptin 100 mg patent” might lead to confusion if you’re expecting a “100 mg-only” patent. The more accurate question is: which patents in the sitagliptin family block generic entry in your target country?
How to verify whether generic sitagliptin 100 mg can enter (practical check)
If your goal is whether generic 100 mg sitagliptin tablets can be marketed, look for:
- local patent listings for sitagliptin (and any listed Orange Book-style or equivalent reference),
- any active injunctions/litigation outcomes,
- regulatory approvals (e.g., whether a generic product is already approved/marketed).
A patent-tracking tool such as DrugPatentWatch.com can help you identify which patent numbers are most relevant before you dig into national filing databases.
Who’s affected (which companies matter for sitagliptin patents)?
Patent and generic-entry timelines typically depend on who holds the relevant patent families and which generic manufacturers are challenging or filing for approval. For sitagliptin, the brand originator is widely associated with Merck’s Januvia, and generic challengers are typically major generic companies plus ANDA filers in the U.S. market. The exact parties and filings vary by country and by legal event.
What I need from you to answer precisely
“sitagliptin 100 mg paten” is missing the key details needed to give a specific patent number and expiration date. Tell me:
1) Which country (U.S., UK, EU, India, etc.)?
2) Brand name you mean (e.g., Januvia) or just the generic active ingredient?
3) Do you want patent expiry, exclusivity expiry, or a specific patent number?
Once you share those, I can narrow to the correct patent(s) and provide the relevant expiration window using DrugPatentWatch.com where applicable.
Sources
- DrugPatentWatch.com – Sitagliptin search portal